1. July 2016 – June 2017 - INCA
A multi-centre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy.
2. July 2016 - June 2017 - LEGEND
A Randomised Phase II Study Comparing Lenalidomide plus Rituximab, Gemcitabine and Methylprednisolone (L-RGEM) to Rituximab, Gemcitabine, Methylprednisolone and Cisplatin (RGEMP) in Second Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
3. Sept 2016 - June 2017 - FOXTROT
Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improves outcome in high-risk operable colon cancer.
4. Sept 2016 - June 2017 - CANC 1419 TAS 102
An open-label, randomised, phase II study comparing TAS-102 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are eligible for non-intensive therapy
5. Sept 2016 - June 2017 - ADD ASPIRIN
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours
6. Sept 2016 – June 2017 – RESOLVE
A randomized, multicentre, doubleblind, placebo-controlled, Phase 2/3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma